STORY / PUBLIC SOURCE RECORD
Norway’s biopharma industry expands its global reach
- Published 28 August 2024; updated 25 March 2026; estimated reading time 5 minutes. The article presents Norwegian biopharma as combining pharmaceutical manufacturing, precision medicine and marine-derived ingredients with sustainability. It estimates health/life-science exports at EUR 2–3 billion. GE HealthCare’s Lindesnes API site planned an USD 80 million expansion to increase iodinated contrast-media capacity 30%, with 30 million additional patient doses targeted by 2025; that target is historical and the page does not confirm completion. Bayer and Thermo Fisher are also named among major export contributors. Vistin Pharma is said to make about 10% of global metformin supply; Palla Pharma makes codeine phosphate; NextPharma acquired a chewable-tablet site in Asker.
- Precision-medicine examples include Oslo Science City/Oslo Cancer Cluster; Caedo Oncology’s monoclonal-antibody cancer therapies based on Oslo University Hospital research; Curida’s nasal sprays, liquid drugs and monoclonal antibodies and a 2024 Signet Healthcare Partners investment; Nykode’s cancer vaccine/immunotherapy work, including a 2024 MSD clinical collaboration and agreements with Regeneron, Genentech and Nektar; Bayer’s Xofigo (radium-223) and continued Norwegian production/research; and Tribune Therapeutics’ fibrosis drug programme, launched in 2021 from Oslo University Hospital research with HealthCap and Novo Seeds backing. These are company programmes and research, not claims of approved treatments except where the page describes an existing medicine.
- Marine/“blue” biopharma examples: Ocean TuniCell farms tunicates off Norway to produce medical-grade nanocellulose scaffolding for wound care, cell therapy and organ reconstruction; ArcticZymes develops cold-adapted marine enzymes for research, diagnostics and therapies. Arctic Bioscience extracts compounds from herring roe byproduct; Aker BioMarine produces krill ingredients; and Zooca/Calanus harvests Calanus finmarchicus for human supplements and aquaculture feed. The article describes renewable power, clean water, electrification, waste reduction, byproduct reuse and hospital/clinic take-back schemes as sustainability attributes of Norwegian production.
- Contact block not shown. Related industry: Health and life science; multiple linked company solutions and related articles.